Results 191 to 200 of about 1,064,547 (319)

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer. [PDF]

Clin Cancer Res
Rubinstein MM, Ge JY, Zhou Q, Iasonos A, Weigelt B, Selenica P, Muldoon DM, Bandlamudi C, Kaczynski C, Paroder V, Higgins K, Shah P, Weissblum S, Lyn A, Liu YL, Bose S, Cohen SM, Green AK, Grisham RN, Kyi C, O'Cearbhaill RE, Tew WP, Berger MF, Aghajanian C, Makker V.   +24 more
europepmc   +1 more source

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates

FEBS Letters, EarlyView.
Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley   +1 more source

Author Correction: Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice

Nature Communications
Sara Ranjbarvaziri, Aliya Zeng, Iris Wu, Amara Greer-Short, Farshad Farshidfar, Ana Budan, Emma Xu, Reva Shenwai, Matthew Kozubov, Cindy Li, Melissa Van Pell, Francis Grafton, Charles E MacKay, Xiaomei Song, James R Priest, Gretchen Argast, Mohammad A. Mandegar, Timothy Hoey, Jin Yang   +18 more
doaj   +1 more source

Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for? [PDF]

Clin Kidney J
Barratt J, Floege J, Lafayette R, Reich HN, Tesař V, Trimarchi H, Wadhwani S.   +6 more
europepmc   +1 more source

Modelling stem cell differentiation related processes—A practical overview for biologists

FEBS Letters, EarlyView.
Stem cell differentiation is complex and difficult to control experimentally. This review introduces suitable computational modelling approaches that can support stem cell research, from mechanistic ODE and abstract models to multiscale and deep learning methods.
Ricco Zeegelaar, Xinqi Yan, Lucas F. Jansen Klomp, Stefano Schivo, Janine N. Post   +4 more
wiley   +1 more source

Publisher Correction: Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia. [PDF]

Genome Biol
Rathgeber AC, Fernandes SM, Nagler A, Li S, Dorfman DM, Bullinger L, Davids MS, Brown JR, Livak KJ, Ludwig LS, Wu CJ, Penter L.   +11 more
europepmc   +1 more source

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. [PDF]

ESMO Open
Im SA, Kalinsky K, Jhaveri KL, Loibl S, Turner N, Saura C, Schmid P, Loi S, Hamilton E, Karadurmus N, Wang S, Awan AA, Ciruelos EM, Chung CF, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Juric D.   +19 more
europepmc   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

FEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens, Brendan W. Chandler, Anna M. Schmoker, Jaye L. Weinert, Charlotte A. Kearns, Warren T. Yacawych, Amila Šemić, Alicia M. Ebert, Bryan A. Ballif   +8 more
wiley   +1 more source

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. [PDF]

J Immunother Cancer
Naing A, Lin CC, Patel MR, Curigliano G, Burris HA, Thistlethwaite F, De Braud F, Minchom A, Ascierto PA, Wake M, Nguyen MA, Abbadessa G, Sainson RCA, Palu CC, Quaratino S, Deantonio C.   +15 more
europepmc   +1 more source